<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> (IR) and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (MS) are associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and adverse <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) risk factor profiles </plain></SENT>
<SENT sid="1" pm="."><plain>Whether IR and MS predict <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> independently of <z:mp ids='MP_0002055'>diabetes</z:mp> and other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk factors is not known </plain></SENT>
<SENT sid="2" pm="."><plain>This study examines whether IR and/or presence of MS are independently associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in nondiabetic American Indians (AI) </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: We examined 2283 nondiabetic AI who were free of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> at the baseline examination of the Strong Heart Study (SHS) </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk factors were measured, IR was quantified using the homeostasis model assessment (HOMA), and MS as defined by the National Cholesterol Education Program Adult Treatment Panel (ATP III) was assessed for each participant </plain></SENT>
<SENT sid="5" pm="."><plain>Incident <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and <z:mp ids='MP_0002055'>diabetes</z:mp> were ascertained during follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: MS was present in 798 individuals (35%), and 181 participants (7.9%) developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> over 7.6 +/- 1.8 years of follow-up </plain></SENT>
<SENT sid="7" pm="."><plain>Age, BMI, waist circumference, and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels increased and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> decreased across tertiles of HOMA-IR </plain></SENT>
<SENT sid="8" pm="."><plain>Risk of <z:mp ids='MP_0002055'>diabetes</z:mp> increased as a function of baseline HOMA-IR (6.3, 14.6, and 30.1%; P &lt; 0.001) and MS (12.8 vs. 24.5%) </plain></SENT>
<SENT sid="9" pm="."><plain>In Cox models adjusted for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk factors, risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> did not increase either as a function of baseline HOMA-IR or MS, but individual <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk factors predicted subsequent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Among nondiabetic AI in the SHS, HOMA-IR and MS both predict <z:mp ids='MP_0002055'>diabetes</z:mp>, but neither predicts <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> independently of other established <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk factors </plain></SENT>
</text></document>